AbbVie Analysts Raise Price Target After Q3 Print, Expect Growth To Reaccelerate
AbbVie shares fell 2% despite Q3 revenue and EPS beats; analysts raised targets, citing immunology strength and long-term growth prospects.
Share
Why It Matters
AbbVie beat what people expected this quarter and analysts think it will grow faster soon. When analysts raise their price targets, it means they believe the company is on a good path forward.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.